Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool aims to predict cancer treatment toxicity in older patients

NCT ID NCT06344208

Recruiting now Knowledge-focused Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new tool designed to predict side effects from cancer treatment in elderly patients (70+) with advanced head and neck cancer. The goal is to see if the tool can help doctors choose safer treatments. Only 3 participants are being enrolled, making this a very early-stage validation study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict which elderly patients are at risk of severe side effects from cancer treatment, leading to more personalized care.
What could go wrong
This is a very small, early study with only 3 participants, so results may not apply to all patients. The tool may not be accurate enough to change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer head and neck carcinoma Head and Neck Neoplasms head and neck squamous cell carcinoma undifferentiated carcinoma of nasopharynx

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • European Institute of Oncology

    RECRUITING

    Milan, Milan, 20141, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.